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The puzzle of sharing bio-molecular targets between coronaviruses and mediators of the
cardiovascular system in humans: Looking for plausible hypotheses
The emerging of SARS-CoV-2 and COVID-19 pandemia with a high
mortality rate in older subjects with one or more known cardiovascular
comorbidities [1] has prompted the question of “sharing bio-molecular
targets” between coronaviruses and Renin Angiotensin Aldosterone
System (RAAS), a system that is involved, at multiple levels, in the
control of the cardiovascular function and, also, is a favorite drug target
in cardiovascular diseases [2]. Indeed during treatment with Angio-
tensin-Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor
Blockers (ARBs) the known up-regulation of ACE2/Ang 1-7/MasR axes
might be very useful to treat arterial blood pressure, ischemic heart
disease and heart failure but, at the same time, detrimental since during
COVID-19 it might open the route to SARS-CoV-2 that have been
proven to use the ACE2 as functional receptor to enter the human cells
[3]. This evidence at the bimolecular level has generated several
commentary-style articles that claim it is more prudent to replace ACEi/
ARBs during COVID-19 [2,4–6]. The main scientific societies have
taken a critical position towards any therapeutic change in the absence
of supporting data [7] and this is dictated by prudence. Nonetheless it
should be said that switching can be done safely in arterial hyperten-
sion if the new drug is 1-well tolerated and a 2-good blood pressure
control is achieved thus, during COVID-19, this switch, is again, a
prudent position if we exclude to switch-off ACEi/ARBs in subjects with
ischemic heart disease and heart failure [8] where we have no other
valid therapeutic choices. Nonetheless a recent report claims that ACE2
is highly expressed in subjects with heart failure indicating a suscept-
ibility to SARS-CoV-2 infection in these subjects [9] questioning, again,
the idea of maintaining such therapy, even in people with heart failure.
This preamble clearly highlights the problem that is coronaviruses
competition with drugs targeting RAAS, but the coin has two sides, and we
don’t know, till now, whether ACEi/ARBs might be detrimental or
useful, thus the question is a little bit more complex and it seems ne-
cessary to produce sustainable hypotheses.
On the reasons of sharing.
(a) It is a “coincidence due to the spread-over-species and ancient-
phylogeny” of Renin-Angiotensin System” [2]. This hypothesis is
sustainable as RAAS is very diffuse over species and ACE2 expres-
sion in the airways makes it a possible target, but to prove.
(b) It is the consequence of the widespread use od drugs that increase
ACE2 expression. This hypothesis is sustainable, exposing targets,
especially in the airways where ACE2 is significantly expressed
[10], may have facilitated the pathway to the coronavirus that, as
any RNA viruses, exhibit a high mutation rate which guarantees the
selection of efficient clones capable of infecting the host, but, again,
to prove.
(c) It is a spillover from a laboratory. Leaving aside conspiracies on
biological war, as we know, in the late nineties, developing stra-
tegies were aimed at modulating SRA at a genetic level, by using
modified viruses targeting ACE2 to treat arterial hypertension and,
more recently, to manipulate coronaviruses to better understand its
virulence, are these strategies at the origin of the spillover? In a
Correspondence to Nature Medicine Kristian G. Andersen et al.
[11], states no with the phrase that I quote “It is improbable that
SARS-CoV-2 emerged through laboratory manipulation of a related
SARS-CoV-like coronavirus”. But “improbable” does not help us to
remove all doubts, since we have learned the Popper's lesson: “one
theory is scientific to the extent that can be disproved”. Again, to
prove.
On the effects of sharing.
(d) Is the high mortality rate for elderly subjects with the coexistence of
comorbidities, among witch high blood pressure is present in more
than 70%, related to the use of ACEi/ARBs? This is in theory pos-
sible but to prove. In the Italian subset of data from the Italian
Health Institute [12] the use of ACEi/ARBs is documented in 52%
and, obviously, not in 49%, thus, this is not a proof, we need more
data and we asked Dr. Wei-jie Guan, the Author of one of the first
report on COVID-19 in China [1], and he replied by email “In our
study, we did not record the use of ARBs given the urgency of data
extraction. We do, however, believe that there is a need to investigate the
association between the use of ACEI or ARB and the clinical outcomes of
Covid-19. In fact, we are planning to conduct a clinical trial on re-
combinant ACE in patients with Covid-19”. Finally, we have also data
supporting potentials benefit of ACEi/ARBs on target organ damage
[13] since RAAS is involved in the cytokine cascade and in the
response to damage [14,15] thus we cannot exclude that the ad-
vantages outweigh the disadvantage.
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